CoChat

Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trials

Wang, Y., Li, L., Yang, M., Liu, H., Boden, G., Yang, G. · 2011 · Diabetes, Obesity and Metabolism
Cited by 30

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

To compare the effect and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) with insulin therapy on type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin and/or sulfonylurea. A systematic literature search on MEDLINE, Embase and Cochrane for randomized controlled trials (RCTs) was conducted using specific search terms ‘GLP‐1 insulin type 2 diabetes clinical trials' and eight eligible studies were retrieved. Data on mean change in haemoglobin A1c (HbA1C), weight loss, fasting plasma glucose (FPG), incidence of hypoglycaemia and gastrointestinal adverse events were extracted from each study and pooled in meta‐analysis. Data on postprandial plasma glucose (PPG) and adverse events were also described or tabulated. Data from eight RCTs enrolling 2782 patients were pooled using a random‐effects model. The mean net change [95% confidence interval (CIs)] for HbA1c, weight loss and FPG for patients treated with GLP‐1 RA as compared with insulin was −0.14% (−2 mmol/mol) [95% CI; (−0.27, −0.02)%; p = 0.03]; −4.40 kg [95% CI; (−5.23, −3.56) kg; p < 0.01] and 1.18 mmol/l [95% CI; (0.43, 1.93) mmol/l; p < 0.01], respectively, with negative values favouring GLP‐1 and positive values favouring insulin. The GLP‐1 group was associated with a greater reduction in PPG than the insulin group. Overall, hypoglycaemia was reported less in the GLP‐1 group [Mantel–Haenszel odds ratio (M‐H OR) 0.45 (0.27, 0.76); p < 0.01], while there was no significant difference in occurrence of severe hypoglycaemia [M‐H OR 0.65 (0.29,1.45); p = 0.29]. A significantly higher number of gastrointestinal adverse events were reported with GLP‐1 group [M‐H OR 15.00 (5.44,41.35) p < 0.01]. GLP‐1 RA are promising new agents compared with insulin. Further prospective clinical trials are expected to fully evaluate the long‐term effectiveness and safety of these therapies within the T2DM treatment paradigm.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01436.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 30

Metadata

Authors
Wang, Y., Li, L., Yang, M., Liu, H., Boden, G., & Yang, G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-09-28
Volume
13
Issue
11
Pages
972-981
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2139496212
Cited by
30
References
9
FWCI
2.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trials. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01436.x
The paper
Wang, Y., Li, L., Yang, M., Liu, H., Boden, G., & Yang, G. (2011). Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01436.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.